rs11556924 — ZC3HC1 R363H

Missense variant in ZC3HC1/NIPA altering cell cycle regulation; the T (His363) allele is protective against coronary artery disease (OR 0.90, p=2.4×10⁻¹⁷)

See your personal result for ZC3HC1

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

ZC3HC1 R363H — A Cell Cycle Regulator at the Heart of CAD Risk

Hidden in the machinery that controls cell division is an unexpected player in coronary artery disease. The ZC3HC1 gene11 ZC3HC1 gene
encodes NIPA — Nuclear Interaction Partner of ALK — a protein that governs when cells transition into mitosis by controlling the nuclear accumulation of cyclin-B1, the key trigger of cell division. The rs11556924 variant swaps a single amino acid at position 363 — arginine to histidine — and this seemingly small change has genome-wide significant consequences for coronary artery disease risk.

This locus is unusual among cardiovascular GWAS hits. Most CAD-associated variants sit in regulatory regions of uncertain function, but rs11556924 is a direct coding change: the only nonsynonymous SNP in the landmark CARDIoGRAM consortium meta-analysis22 CARDIoGRAM consortium meta-analysis
22,233 CAD cases and 64,762 controls of European ancestry that identified 13 new susceptibility loci. The T allele (His363) carries an odds ratio of 0.90 for CAD — a 10% reduction in risk per allele — with a p-value of 2.4×10⁻¹⁷.

The Mechanism

NIPA acts as a molecular brake on mitotic entry. In dividing cells, cyclin-B1 must accumulate in the nucleus before cell division can proceed. NIPA controls the rate of this nuclear entry by responding to CDK1-mediated phosphorylation33 CDK1-mediated phosphorylation
Cyclin-dependent kinase 1, the master regulator of mitosis. When CDK1 phosphorylates NIPA at Ser-395, it inactivates NIPA, allowing cyclin-B1 to accumulate and mitosis to proceed.

The R363H substitution alters this regulatory circuit. In cells carrying the risk C allele (Arg363), CDK1-mediated phosphorylation at Ser-395 is significantly slower (p=0.002), meaning NIPA remains active longer. Active NIPA holds cyclin-B1 out of the nucleus, reducing its stability there and slowing nuclear accumulation. The net result: risk-allele cells take approximately 3.4 additional minutes to complete mitosis compared to protective-allele cells (p=0.011).

The protective T allele (His363) shows a different phosphorylation profile. Functional validation using isogenic genome-edited cell lines44 Functional validation using isogenic genome-edited cell lines
identical cells differing only at rs11556924 demonstrated that His363 NIPA has increased phosphorylation at Ser354, higher protein expression, and greater nuclear mobility — all consistent with faster inactivation and more permissive cell cycle control. Critically, His363 cells show reduced proliferation, which is the proposed mechanism of cardiovascular protection.

In vascular biology, the stakes are high. Vascular smooth muscle cells (VSMCs)55 Vascular smooth muscle cells (VSMCs)
the primary cell type in the arterial wall undergo phenotypic switching from quiescent contractile cells to proliferative, migratory synthetic cells during atherogenesis. ZC3HC1 deficiency in VSMCs increases migration and promotes neointima formation — the hallmark of atherosclerotic plaque development — while also modulating cyclin-B1 levels and the SRF contractile gene program. Altered cell cycle control by the Arg363 variant may therefore sustain VSMC proliferation in the arterial wall, accelerating plaque growth.

The Evidence

The primary evidence comes from the CARDIoGRAM GWAS meta-analysis66 CARDIoGRAM GWAS meta-analysis
Coronary ARtery DIsease Genome-wide Replication And Meta-analysis consortium, which combined 14 individual GWAS studies totaling 22,233 cases and 64,762 controls. Of the 13 newly identified loci, rs11556924 in ZC3HC1 was the sole coding variant, making it particularly tractable for functional follow-up. The OR of 0.90 per T allele is consistent across replication cohorts and represents a robustly replicated GWAS signal.

Beyond CAD, the C allele has been associated with hypertension in the Finnish TAMRISK cohort77 hypertension in the Finnish TAMRISK cohort
769 participants at age 50, OR 1.42 for hypertension in CC carriers vs T allele carriers, 95% CI 1.10–1.84, suggesting effects on vascular function extend to blood pressure regulation. The T allele frequency varies markedly by ancestry: approximately 38% in Europeans, but only 5% in East Asians and 8% in Africans. This means about 43% of Europeans are homozygous CC, carrying the full two-dose risk.

The T allele frequency of 38% in Europeans means this is a common protective variant — the population-level effect is substantial. Each copy of the T allele reduces CAD risk by approximately 10%, and TT homozygotes (10% of Europeans) carry roughly 18% lower risk than CC homozygotes.

Practical Actions

The CAD-protective mechanism of the His363 variant operates through slower cell proliferation and altered VSMC phenotype. While carriers of the risk CC genotype cannot change their genotype, several interventions target the same cell cycle and vascular smooth muscle pathways implicated by this variant.

Monitoring cardiovascular risk factors — particularly blood pressure — is especially relevant for CC carriers. The TAMRISK data link CC to elevated hypertension risk, and blood pressure control is one of the most effective ways to reduce atherosclerotic progression independent of the genetic mechanism.

Omega-3 fatty acids (EPA and DHA) modulate VSMC phenotype and reduce proliferation through mechanisms that overlap with the ZC3HC1/cyclin-B1 pathway, including suppression of VSMC migration. Aspirin and antiplatelet therapy may also address the platelet-function dimensions of this variant's cardiovascular effects.

Interactions

ZC3HC1 operates within the broader cell cycle control network. The CDK1 pathway that phosphorylates NIPA is regulated by multiple upstream signals, and variants in cell cycle checkpoint genes could theoretically compound or mitigate ZC3HC1's effects. However, no published compound-action evidence currently exists for this specific interaction.

For cardiovascular risk, ZC3HC1 rs11556924 adds to polygenic scores alongside established CAD loci including rs4977574 (CDKN2A/B), rs9349379 (PHACTR1), and rs1333049 (9p21). These loci act through independent mechanisms — the 9p21 locus affects CDKN2A/B (cell cycle inhibitors), creating a potential directional interaction: individuals carrying risk alleles at both the 9p21 locus and ZC3HC1 face additive CAD risk through converging cell cycle dysregulation, though quantified compound-genotype risk estimates are not yet available in the published literature.

Genotype Interpretations

What each possible genotype means for this variant.

TT His363 Homozygous Beneficial

Lowest CAD risk at this locus — both alleles carry the protective His363 variant

The TT genotype at rs11556924 represents the most protective state at this locus. Both copies of your NIPA protein carry histidine at position 363. Isogenic cell line studies demonstrate that His363 NIPA: (1) is phosphorylated more rapidly at Ser354 under CDK1 activity, (2) shows higher total protein expression, (3) has greater nuclear mobility, and (4) is associated with reduced overall cell proliferation rate. These properties collectively result in tighter regulation of nuclear cyclin-B1 accumulation — the His363 variant applies the cell cycle brake more effectively.

In the vascular context, this translates to reduced VSMC proliferative activity, which is the mechanistic basis for the 10% per-allele CAD risk reduction observed across the CARDIoGRAM meta-analysis and replication cohorts. TT homozygotes at this locus are among the minority with genetically optimized VSMC cell cycle regulation — a meaningful advantage given that VSMC proliferation is a rate-limiting step in atherosclerotic plaque development.

CT Arg/His Heterozygous Intermediate

Moderate CAD risk reduction with one protective His363 allele

The CT genotype places you in an intermediate risk category. The T allele's His363 NIPA form has higher baseline phosphorylation at Ser354 and greater nuclear mobility compared to Arg363, contributing partial inactivation speed to the overall cellular pool. Studies in heterozygous isogenic cell lines show intermediate mitotic timing between CC and TT cells.

For cardiovascular outcomes, the additive inheritance pattern means each T allele independently reduces CAD risk by ~10%. CT carriers have approximately 10% lower CAD risk than CC homozygotes and 10% higher risk than TT homozygotes. This modest partial protection is meaningful at the population level but does not eliminate the need for cardiovascular monitoring and risk factor management.

CC Arg363 Homozygous High Risk

Higher CAD risk from reduced cell cycle braking in vascular smooth muscle

The CC genotype means both copies of your NIPA protein carry arginine at position 363. Functional studies using isogenic cell lines demonstrate that Arg363 NIPA is phosphorylated more slowly by CDK1 at the Ser-395 regulatory site compared to His363. Because phosphorylation of this site inactivates NIPA's cell cycle braking function, slower phosphorylation means NIPA remains active longer — restricting cyclin-B1's nuclear entry and slowing mitotic progression by approximately 3.4 minutes per cell division cycle.

While a 3.4-minute difference may sound trivial, its cumulative effect on rapidly dividing vascular smooth muscle cells in atherogenic conditions matters. VSMC proliferation and migration are hallmarks of neointima formation — the core cellular event in atherosclerotic plaque buildup. ZC3HC1 deficiency experiments in mice produced approximately 2-fold greater neointima formation, confirming NIPA's gating role in this process.

The blood pressure association adds another dimension: the TAMRISK study found CC carriers had OR 1.42 for hypertension at age 50, suggesting ZC3HC1's cell cycle role extends to vascular tone regulation. Hypertension itself accelerates atherosclerosis, so CC carriers face a compounded vascular risk profile.